Total testosterone
ng/dL
Baseline
412
Follow-up
782
Change
↑ +370+90%
Labs analysis
Your results are ranged against longevity targets and laboratory reference intervals. The 53 priority markers below include the full values and clinical interpretation from your 153-marker panel.
82
Optimal
54
In range
17
Out of range
153 markers tested - latest panel released 12 September 2026
Markers moved into optimal
44
of 53 priority markers
Out of range at baseline
6
flagged for intervention
Out of range at follow-up
0
remaining watch items
Chain of review - Comprehensive Baseline Panel - 153 markers
ReleasedSpecimen received
13 March 2026
Precision Analytics Laboratory
Reviewed & signed
16 March 2026 · 09:42
Dr. Alan R. Whitfield, MD - Internal Medicine · Longevity Medicine
Released to patient
16 March 2026
Visible in the client Vault
Signature on file
A. R. Whitfield
License #IM-448120
Chain of review - Follow-up Panel - 153 markers
ReleasedSpecimen received
10 September 2026
Precision Analytics Laboratory
Reviewed & signed
12 September 2026 · 08:15
Dr. Alan R. Whitfield, MD - Internal Medicine · Longevity Medicine
Released to patient
12 September 2026
Visible in the client Vault
Signature on file
A. R. Whitfield
License #IM-448120
Result ranges
Endocrine - full axis
The whole axis, not just total testosterone: binding proteins, pituitary signalling, aromatisation and downstream androgens.
ng/dL
Baseline
412
Follow-up
782
Change
↑ +370+90%
pg/mL
Baseline
61
Follow-up
168
Change
↑ +107+175%
ng/dL
Baseline
148
Follow-up
361
Change
↑ +213+144%
nmol/L
Baseline
52
Follow-up
33
Change
↓ −19−37%
g/dL
Baseline
4.1
Follow-up
4.6
Change
↑ +0.5+12%
ratio
Baseline
27
Follow-up
82
Change
↑ +55+204%
IU/L
Baseline
2.1
Follow-up
4.4
Change
↑ +2.30+110%
IU/L
Baseline
2.4
Follow-up
3.6
Change
↑ +1.20+50%
pg/mL
Baseline
14
Follow-up
26
Change
↑ +12+86%
ratio
Baseline
29.4
Follow-up
30.1
Change
↑ +0.70+2%
µg/dL
Baseline
188
Follow-up
372
Change
↑ +184+98%
ng/mL
Baseline
13.8
Follow-up
8.1
Change
↓ −5.70−41%
ng/mL
Baseline
0.14
Follow-up
0.31
Change
↑ +0.17+121%
ng/mL
Baseline
0.8
Follow-up
0.9
Change
↑ +0.10+12%
Clinical evaluation
Dr. Alan R. Whitfield, MD
What the numbers said
At baseline John presented with low-normal total testosterone and genuinely low free testosterone, driven by high SHBG binding most of what he produced. LH sat at the bottom of range, so the pituitary was not pushing the testes hard. Prolactin was borderline high, which suppresses that signal further.
Why it matters
Free testosterone - not total - is what reaches tissue. In this range men report flat drive, poor recovery between training sessions, visceral fat that will not move, and worsening insulin sensitivity. Left alone the axis usually drifts further with age.
What changed by follow-up
Free testosterone rose from 61 to 168 pg/mL with SHBG down from 52 to 33 nmol/L, LH restored into mid-range, prolactin normalised, and estradiol brought up into the protective 20-30 pg/mL window rather than crushed. The T:E2 ratio was deliberately held stable.
What we did
Sleep and circadian correction first, then insulin-sensitivity work through nutrition, resistance training three times weekly with progressive overload, boron and zinc to reduce SHBG binding, and physician-supervised axis support with monthly monitoring.
Longevity - atherogenic burden
Particle-based risk, not just a standard cholesterol panel. ApoB and Lp(a) drive lifetime cardiovascular exposure.
mg/dL
Baseline
118
Follow-up
71
Change
↓ −47−40%
nmol/L
Baseline
46
Follow-up
44
Change
↓ −2−4%
Largely genetic - tracked, not chased.
nmol/L
Baseline
1486
Follow-up
940
Change
↓ −546−37%
mg/dL
Baseline
142
Follow-up
84
Change
↓ −58−41%
mg/dL
Baseline
42
Follow-up
58
Change
↑ +16+38%
mg/dL
Baseline
186
Follow-up
74
Change
↓ −112−60%
ratio
Baseline
4.4
Follow-up
1.3
Change
↓ −3.10−70%
mg/dL
Baseline
34
Follow-up
13
Change
↓ −21−62%
%
Baseline
4.2
Follow-up
8.9
Change
↑ +4.7+112%
Clinical evaluation
Dr. Alan R. Whitfield, MD
What the numbers said
Baseline showed an atherogenic pattern: ApoB 118 mg/dL with LDL particle number well above range, triglycerides high and HDL low - the classic insulin-resistant lipid signature rather than a purely dietary-cholesterol picture.
Why it matters
ApoB counts the number of artery-penetrating particles. Cumulative ApoB exposure over decades is the single strongest modifiable driver of cardiovascular events. Trig:HDL above 3 also flags insulin resistance years before glucose moves.
What changed by follow-up
ApoB fell 47 mg/dL into the optimal band, triglycerides more than halved, Trig:HDL dropped from 4.4 to 1.3, and the omega-3 index moved from deficient to protective. Lp(a) is genetically set and unchanged - it stays on the watch list and raises the target aggressiveness for everything else.
What we did
Carbohydrate quality and timing restructured around training, saturated fat reduced in favour of monounsaturated sources, 3 g/day EPA/DHA, zone-2 cardio four hours weekly, and a repeat particle panel at 90 days before any pharmacological step was considered.
Longevity - glycaemic control
Insulin resistance and systemic inflammation - the two engines behind most age-related decline.
µIU/mL
Baseline
14.2
Follow-up
4.6
Change
↓ −9.6−68%
index
Baseline
3.4
Follow-up
1
Change
↓ −2.4−71%
mg/dL
Baseline
98
Follow-up
86
Change
↓ −12−12%
%
Baseline
5.6
Follow-up
5.1
Change
↓ −0.5−9%
mg/L
Baseline
2.8
Follow-up
0.5
Change
↓ −2.3−82%
µmol/L
Baseline
12.4
Follow-up
7.6
Change
↓ −4.80−39%
mg/dL
Baseline
6.9
Follow-up
5.2
Change
↓ −1.7−25%
ng/mL
Baseline
96
Follow-up
148
Change
↑ +52+54%
ng/mL
Baseline
11.8
Follow-up
4.1
Change
↓ −7.70−65%
Clinical evaluation
Dr. Alan R. Whitfield, MD
What the numbers said
HOMA-IR of 3.4 with fasting insulin at 14.2 µIU/mL placed John firmly in insulin resistance despite a glucose and HbA1c a standard physical would have called normal. hs-CRP and homocysteine confirmed low-grade systemic inflammation.
Why it matters
Insulin resistance precedes type 2 diabetes by a decade or more and is simultaneously suppressing the testosterone axis, raising ApoB and accelerating biological ageing. This is where most of the leverage is.
What changed by follow-up
Fasting insulin down 68%, HOMA-IR into the optimal band, hs-CRP down to 0.5 mg/L, homocysteine normalised, and IGF-1 lifted from the low end into the mid-range target rather than pushed high.
What we did
Protein-forward meal structure with a 12-hour eating window, post-meal walking, resistance training as the primary glucose-disposal tool, methylated B-complex for homocysteine, and magnesium repletion.
Systems - capacity and clearance
Liver, kidney and thyroid capacity - the systems that must tolerate any protocol before it is escalated.
U/L
Baseline
44
Follow-up
22
Change
↓ −22−50%
U/L
Baseline
34
Follow-up
24
Change
↓ −10−29%
U/L
Baseline
41
Follow-up
18
Change
↓ −23−56%
mL/min/1.73
Baseline
88
Follow-up
98
Change
↑ +10+11%
mg/L
Baseline
0.94
Follow-up
0.78
Change
↓ −0.16−17%
mg/g
Baseline
14
Follow-up
6
Change
↓ −8−57%
mIU/L
Baseline
3.2
Follow-up
1.6
Change
↓ −1.6−50%
pg/mL
Baseline
2.6
Follow-up
3.5
Change
↑ +0.9+35%
ng/dL
Baseline
1
Follow-up
1.3
Change
↑ +0.30+30%
ng/dL
Baseline
22
Follow-up
13
Change
↓ −9−41%
Clinical evaluation
Dr. Alan R. Whitfield, MD
What the numbers said
GGT and ALT elevated together with a high reverse T3 and low free T3 - a pattern of hepatic fat and a body downshifting its own thyroid conversion under metabolic and sleep stress, not primary thyroid disease.
Why it matters
Reverse T3 rising while free T3 falls is the body throttling metabolic rate. Treating it as a thyroid problem misses the cause. Kidney filtration measured by cystatin C rather than creatinine alone gives a truer picture in a muscular client.
What changed by follow-up
GGT more than halved, ALT and AST into the optimal band, free T3 up to 3.5 pg/mL with reverse T3 down to 13, and cystatin C-derived filtration improved. No thyroid medication was used.
What we did
Alcohol removed for the first 90 days, hepatic fat addressed through the metabolic protocol, selenium and iodine sufficiency confirmed, sleep extended to 7.5 hours, and training volume periodised to reduce chronic stress load.
Foundations - substrate availability
The raw materials the protocol depends on. A deficient substrate caps every other result.
ng/mL
Baseline
22
Follow-up
62
Change
↑ +40+182%
pg/mL
Baseline
318
Follow-up
664
Change
↑ +346+109%
ng/mL
Baseline
6.1
Follow-up
14.2
Change
↑ +8.1+133%
mg/dL
Baseline
4.4
Follow-up
5.9
Change
↑ +1.5+34%
µg/dL
Baseline
71
Follow-up
104
Change
↑ +33+46%
ng/mL
Baseline
214
Follow-up
118
Change
↓ −96−45%
%
Baseline
47
Follow-up
33
Change
↓ −14−30%
g/dL
Baseline
14.6
Follow-up
15.4
Change
↑ +0.80+5%
%
Baseline
43.1
Follow-up
46.2
Change
↑ +3.10+7%
K/µL
Baseline
7.9
Follow-up
5.6
Change
↓ −2.30−29%
K/µL
Baseline
289
Follow-up
264
Change
↓ −25−9%
Clinical evaluation
Dr. Alan R. Whitfield, MD
What the numbers said
Vitamin D frankly deficient at 22 ng/mL, RBC magnesium and zinc both low, and ferritin with transferrin saturation running high - iron loading rather than iron deficiency.
Why it matters
Low D and zinc directly limit androgen production and immune function; low RBC magnesium limits sleep quality and glucose handling. High ferritin with high saturation is an oxidative-stress load that quietly accelerates ageing.
What changed by follow-up
Vitamin D into the 50-80 ng/mL target, magnesium and zinc repleted, ferritin brought from 214 to 118 ng/mL with saturation normalised. Haemoglobin and haematocrit stayed inside the safe band throughout axis support - monitored specifically for that reason.
What we did
Vitamin D3 with K2 titrated to level, magnesium glycinate at night, zinc with copper balance, dietary iron moderated with two supervised blood donations, and quarterly re-testing.